CellSpring Information

CellSpring develops blood-based tests for diagnosing early stage cancer. The tests rely on a proprietary exosomal biomarker discovery technology developed at world class research institutes in Switzerland. Detecting cancer early means catching it before a patient even has symptoms -- when the full gamut of therapeutic options is available and most likely to succeed.

Website	http://www.cellspring.co
Revenue	$6 million
Employees	2 (0 on RocketReach)
Founded	2015
Address	Otto-Stern-Weg 7, Zürich ETH-Hönggerberg, Zurich 8093, CH
Phone	+41 76 216 08 21
Technologies	JavaScript , HTML , Twitter +9 more (view full list)
Industry	Biotechnology Research, Medical Testing & Clinical Laboratories, 3D Cell Culture, Healthcare, Preclinical Drug Development
Keywords	Early Cancer Detection, Cancer Diagnostics, Cancer Screening, Early Cancer Diagnosis, Cancer Detection Technology, Liquid Biopsy, Oncology Diagnostics, Cancer Biomarkers, Cancer Testing, Biomarker Discovery, Molecular Diagnostics, Advanced Cancer Diagnostics, Non Invasive Cancer Test, Precision Oncology
Competitors	Roche, Thermo Fisher Scientific, Amgen, Regeneron, Vertex Pharmaceuticals, Illumina, CRISPR Therapeutics, Editas Medicine, Sangamo Therapeutics, Inc., Zymergen, Inc. +43 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 873 Companies
NAICS	NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies